December 2, 2025

The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s Platform (part 2)

The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s Platform (part 2)

About This Episode

In part 2 John Dwyer, CEO of the Global Alzheimer's Platform (GAP), and BrainStorm host Meryl Comer discuss transforming Alzheimer's research and clinical trials. Dwyer shares how the field is shifting toward earlier intervention and leveraging artificial intelligence to improve trial efficiency and accuracy. AI can help identify subtle disease patterns and ensure trials enroll appropriate candidates. GAP is also pioneering remote, decentralized trials that bring research into patients' homes rather than requiring frequent clinic visits, aiming to dramatically scale up participation.

Dwyer also highlights proven lifestyle interventions that support cognitive health alongside pharmaceutical treatments and suggests multiple treatment approaches may soon be available.

This episode of BrainStorm is sponsored by Johnson & Johnson

BrainStorm Feed

101

The Marriage Sabbatical - Finding Love and Living with MCI with Leah Fisher

This episode of BrainStorm, by UsAgainstAlzheimer’s, features host Meryl Comer interviewing Leah Fisher, a psychotherapist and author who took a bold year-long solo travel sabbatical at age 60 to explore different cultures while maintaining her marriage.
LISTEN NOW
100

2025 Year in Review and Predictions for 2026 with George Vradenburg

George Vradenburg, Chairman and Founder of UsAgainstAlzheimer's, sits down with host Meryl Comer for a comprehensive look at the state of Alzheimer's research, advocacy, and care in 2025.
LISTEN NOW
98

The Future of Alzheimer's Trials: Bringing Cutting-Edge Research to Every Community - John Dwyer, CEO of The Global Alzheimer's Platform

John Dwyer, CEO of the Global Alzheimer's Platform (GAP), highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities.
LISTEN NOW